IB Net Payout Yields Model

Invest like me - only at Covestor.com

CoreWeave: Don't Sweat AI Race Hiccups

By -

Update - Jan. 26, 2026

NVDA wisely buying into CRWV at less than 4x '26 sales and close to 2x '27 sales. The market doubting this AI data center story was crazy.

-Nvidia (NVDA) has invested $2B in CoreWeave (CRWV) and expanded their collaboration to help CoreWeave accelerate the buildout of over 5 gigawatts of AI factories by 2030.
-Nvidia invested $2B in CoreWeave Class A common stock at $87.20 per share.

  • Looking for a portfolio of ideas like this one? Members of Out Fox The Street get exclusive access to our subscriber-only portfolios. Learn More »

Original article posted on Nov. 17 

  • CoreWeave remains an ultra Bullish opportunity despite recent stock declines driven by short-term data center delays and AI bubble fears.
  • CRWV reported strong Q3 results, beating estimates with 133% YoY revenue growth, and maintains a massive $55 billion backlog with robust customer demand.
  • Concerns over depreciation schedules and AI sector profitability appear overblown, as CRWV's customer contracts and GPU utility remain strong.
  • With shares trading at just 2x 2027 sales targets and insatiable demand, the current weakness presents a compelling buying opportunity for investors.
The market has a long history of overreacting to short-term disruptions and CoreWeave, Inc. (CRWV) is feeling this pain right now. The neocloud provider got smacked down this week after reporting a solid Q3, but the company guided down for the current quarter due to some new data center delays. My investment thesis remains ultra Bullish as the stock is trading on short-term hiccups while the long-term investment story continues getting better.


Read the full article on Seeking Alpha. 

Disclosure: No position mentioned. Please review the disclaimer page for more details. 

Comments

Post a Comment

Popular posts from this blog

Stat of the Day: VXO hits 45 again

By -
Not hardly a week removed from hitting 45 on 9/18/08 and the market is back to this extreme level. Usually hitting the 40 level has historically been a huge buy signal for at least the next 4-6 months. Below are the times that 40 has been hit and only 2 times did it exceed 45 in the prior 20+ years until this month. Guess time will tell if this one leads to a huge rally. Date High 10/19/1987 152.48 8/24/1990 40.01 10/27/1997 40.04 8/27/1998 41.46 4/14/2000 41.53 3/22/2001 41.99 9/17/2001 47.7 7/11/2002 41.64 9/18/2008 45.81
Read more

Nextdoor: Next Step Up

By -
Image
Update - Feb. 28, 2025 Nextdoor reported another strong quarter.  Q4 Revenue of $65.23M (+17.4% Y/Y)  beats by $2.11M . Adjusted EBITDA was $3.0 million, compared to a $14.0 million loss in the year-ago period, reflecting 30 percentage points of year-over-year margin improvement. The social media company guided to weak Q1 results due to going full speed ahead with the NEXT UI updates. This is great news for  investors, but the stock is down some 30% due to the markets short-term focus.  The stock trades at near cash value of $427 million.  Originally posted on Nov. 8 Looking for a portfolio of ideas like this one? Members of Out Fox The Street get exclusive access to our subscriber-only portfolios.  Learn More » Nextdoor has achieved a significant turnaround under the return of founding CEO Nirav Tolia, with 17% revenue growth and record WAUs. The company nearly eliminated losses, reporting a Q3 adjusted EBITDA loss of just $1 million, and expects to be cas...
Read more

Hims & Hers Health: The Market Is Likely Wrong

By -
Image
Updated - Feb. 21, 2025 Hims & Hers Health isn't reliant on GLP-1 shortages. Not sure why news reports keep making this false claim, but the stock is down 20% today on the FDA ending the semagultide shortage status.  -The U.S. FDA announced Friday that it would refrain from penalizing makers of compounded versions of Novo Nordisk’s (NVO) weight loss/obesity drugs for two more months as supply conditions for the GLP-1s improve after an official end to their shortage. -Earlier in the day, the agency declared that the nationwide shortage of the highly popular GLP-1s, collectively known as semaglutide, is resolved after nearly three years. -“The FDA confirmed with the drug’s manufacturer that their stated product availability and manufacturing capacity can meet the present and projected national demand,” the regulator said. -Hims & Hers (NYSE:HIMS), which made compounded versions of semaglutide amid the shortage, lost billions of dollars in market cap in reaction as the telehea...
Read more